Phycocyanobilin - Center for Genetic Engineering and Biotechnology/Heber Biotech
Latest Information Update: 26 Feb 2016
At a glance
- Originator Center for Genetic Engineering and Biotechnology; Heber Biotec
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cerebral infarction
Most Recent Events
- 01 Dec 2014 Preclinical trials in Cerebral infarction in Cuba (unspecified route)